NanoViricides Inc (NNVC)

Currency in USD
1.580
0.000(0.00%)
Closed·
After Hours
1.600+0.020(+1.24%)
·
NNVC Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
NNVC is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.5601.599
52 wk Range
0.9402.340
Key Statistics
Prev. Close
1.58
Open
1.58
Day's Range
1.56-1.599
52 wk Range
0.94-2.34
Volume
61.83K
Average Volume (3m)
256.41K
1-Year Change
-16.84%
Book Value / Share
0.56
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
NNVC Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

NanoViricides Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy

NanoViricides Inc Company Profile

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company’s product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments. It also offers NV-387 Solution for injection, infusion, and inhalation to treat severe cases that are not hospitalized and carried out by an injection; and injectable solution that delivered directly into the lungs as a fog created using portable battery operated nebulizer devices, which enables action at infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company develops NV-HHV-1, a skin cream for the treatment of Shingles rash, which has completed non-clinical pharmacology studies; oral drug with NV-HHV-1 as the active ingredient for the treatment of HSV-1 cold sores and HSV-2 genital ulcers; and other drug candidates in HIVCide program for the treatment of Dengue and Ebola virus, as well as provides Nanoviricide platform technology to treat various types of viruses. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.

Compare NNVC to Peers and Sector

Metrics to compare
NNVC
Peers
Sector
Relationship
P/E Ratio
−2.6x−3.8x−0.5x
PEG Ratio
−0.17−0.010.00
Price/Book
2.9x2.5x2.6x
Price / LTM Sales
-150.6x3.3x
Upside (Analyst Target)
-196.4%43.5%
Fair Value Upside
Unlock4.3%6.8%Unlock

Earnings

Latest Release
May 16, 2025
EPS / Forecast
-0.14 / -0.19
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

NNVC Income Statement

People Also Watch

247.45
AVAV
-4.68%
18.23
SRPT
+1.50%
2.070
VOR
0.00%
2.000
IPA
+8.11%
51.43
BMNR
+24.59%

FAQ

What Stock Exchange Does NanoViricides Inc Trade On?

NanoViricides Inc is listed and trades on the New York Stock Exchange stock exchange.

What Is the Stock Symbol for NanoViricides Inc?

The stock symbol for NanoViricides Inc is "NNVC."

What Is the NanoViricides Inc Market Cap?

As of today, NanoViricides Inc market cap is 25.39M.

What Is NanoViricides Inc's Earnings Per Share (TTM)?

The NanoViricides Inc EPS (TTM) is -0.69.

When Is the Next NanoViricides Inc Earnings Date?

NanoViricides Inc will release its next earnings report on 02 Sept 2025.

From a Technical Analysis Perspective, Is NNVC a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

How Many Times Has NanoViricides Inc Stock Split?

NanoViricides Inc has split 2 times.

How Many Employees Does NanoViricides Inc Have?

NanoViricides Inc has 7 employees.

What is the current trading status of NanoViricides Inc (NNVC)?

As of 09 Aug 2025, NanoViricides Inc (NNVC) is trading at a price of 1.58, with a previous close of 1.58. The stock has fluctuated within a day range of 1.56 to 1.60, while its 52-week range spans from 0.94 to 2.34.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.